威尼斯人
医学
化疗
内科学
文
耐火材料(行星科学)
长春新碱
急性淋巴细胞白血病
肿瘤科
挽救疗法
白血病
淋巴细胞白血病
环磷酰胺
慢性淋巴细胞白血病
生物
天体生物学
计算机科学
计算机安全
作者
Jonathan Canaani,Avraham Frisch,Daniel A Pollyea,Marc Schwartz,Shlomzion Aumann,Chezi Ganzel,Arnon Haran,Noa Gross Even-Zohar,Adir Shaulov,Vladimir Vainstein,Yakir Moshe,Yishai Ofran,Ofir Wolach,Boaz Nachmias
摘要
Dysregulation of BCL-2 family members has been reported in acute lymphocytic leukemia (ALL), with various BH3-dependencies of the leukemic clone. We conducted a multicenter retrospective cohort of patients with relapsed/refractory B or T ALL, with ven-chemotherapy or ven-navitoclax combinations, to assess efficacy and safety.Seventeen patients were included in the analysis, median age was 32 years, with 6 B-ALL and 11 T-ALL patients. Nine patients received venetoclax combined with chemotherapy, and 13 patients received venetoclax in combination with navitoclax, vincristine and asparaginase, of which 5 were already exposed to venetoclax in previous lines.ORR was 55% and 46% among the ven-chemotherapy and the ven-navitoclax-chemotherapy, respectively. Most of the responders proceeded to an allogenic bone marrow transplant in both cohorts. The most common adverse effects of the ven-navitoclax combination were infectious complications and hepatotoxicity.Our data demonstrated the possible efficacy of ven-chemotherapy and ven-navitoclax in r/r ALL with moderate toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI